Xenon Pharmaceuticals Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDXenon Pharmaceuticals Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings contraction of 41% provides fundamental context to the price action. Investors should exercise caution due to high volatility (60% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $53.78 | +11.80% | ABOVE |
| 50 SMA | $54.88 | +9.56% | ABOVE |
| 100 SMA | $52.76 | +13.96% | ABOVE |
| 150 SMA | $49.46 | +21.57% | ABOVE |
| 200 SMA | $47.01 | +27.91% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is XENE in an uptrend right now?
XENE has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, XENE is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is XENE overbought or oversold?
XENE's RSI (14) is 71. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is XENE outperforming the market?
XENE has a Relative Strength (RS) Rating of 83 out of 99. Yes, XENE is a market leader, outperforming 83% of all stocks over the past 12 months.
Where is XENE in its 52-week range?
XENE is trading at $60.13, which is 94% of its 52-week high ($63.95) and 89% above its 52-week low ($30.00).
How volatile is XENE?
XENE has a Beta of 1.00 and 52-week volatility of 60%. It's more volatile than the S&P 500 - expect bigger swings.